Teleflex (TFX)
(Delayed Data from NYSE)
$242.50 USD
-3.18 (-1.29%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $242.37 -0.13 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$242.50 USD
-3.18 (-1.29%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $242.37 -0.13 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth C Momentum D VGM
Zacks News
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Teleflex's (TFX) Arrow EZ-IO Needle Receives FDA Approval
by Zacks Equity Research
Teleflex's (TFX) Arrow EZ-IO Needle is the first and only intraosseous (IO) needle for MR Conditional labelling.
Teleflex's (TFX) Wattson Temporary Pacing Receives FDA Nod
by Zacks Equity Research
Teleflex's (TFX) Wattson Temporary Pacing Guidewire offers dual functionality, allowing both valve delivery and ventricular bipolar pacing during TAVR or BAV treatments.
Teleflex (TFX) Q1 Earnings Top Estimates, 2023 Sales View Up
by Zacks Equity Research
Teleflex (TFX) registers growth across the majority of its businesses, including double-digit increases in interventional and surgical revenues in Q1.
Teleflex (TFX) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teleflex (TFX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 4.04% and 3.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 71.43% and 26.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sientra (SIEN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sientra (SIEN) delivered earnings and revenue surprises of -137.50% and 2.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Urolift Market Expansion Strong, Cost Woe Stays
by Zacks Equity Research
Teleflex (TFX) plans to spend 2023 training surgeons, building its presence in key cities and continuing to engage with the Chinese Urological Society to build acceptance.
Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Down
by Zacks Equity Research
Teleflex (TFX) revenues in Asia rise backed by strong contributions from growth in all geographies.
Teleflex (TFX) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 2.33% and 0.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 1.08% and 0.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Teleflex (TFX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Teleflex (TFX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights Comcast, Aon, Trane Technologies, Huntington Bancshares and Teleflex
by Zacks Equity Research
Comcast, Aon, Trane Technologies, Huntington Bancshares and Teleflex are part of the Zacks top Analyst Blog.
Top Analyst Reports for Comcast, Aon & Trane Technologies
by Santanu Roy
Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), Aon plc (AON) and Trane Technologies plc (TT).
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) on strong preference for the UroLift system.
Teleflex (TFX) OEM Arm Grows, Supply Issue Persists
by Zacks Equity Research
From a geographic perspective, Teleflex (TFX) is seeing strong results in Asia, which continues to be an important growth driver for Teleflex.
Glaukos (GKOS) Up 0.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teleflex (TFX) Q3 Earnings Top Estimates, Adjusted EPS View Cut
by Zacks Equity Research
For UroLift, Teleflex (TFX) currently assumes 2022 revenues to be roughly $320 million, down from the prior guidance of $335 million.
Teleflex (TFX) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 5.48% and 0.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Abiomed (ABMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Abiomed (ABMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex (TFX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Teleflex (TFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tactile Systems Technology (TCMD) Moves 6.6% Higher: Will This Strength Last?
by Zacks Equity Research
Tactile Systems Technology (TCMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Teleflex (TFX) Witnesses Lower UroLift Sales, Cost Woes
by Zacks Equity Research
Teleflex's (TFX) lowered revenue and adjusted EPS outlook for 2022 indicates lackluster performance, which increases investors' concern.